A newly disclosed cancer study had "unprecedented" and "unheard-of" results, and now all eyes are on dostarlimab, the GlaxoSmithKline drug used to achieve complete remission in the trial. Developed by ...

Please provide your email address to receive an email when new articles are posted on . A regimen containing dostarlimab plus standard-of-care chemotherapy significantly improved OS compared with ...

Please provide your email address to receive an email when new articles are posted on . A head-to-head trial of the PD-1 inhibitors dostarlimab and pembrolizumab, each in combination with chemotherapy ...

Credit: Getty Images. Treatment with dostarlimab plus carboplatin-paclitaxel reduced the risk of disease progression by 72% in the dMMR/MSI-H population. The Food and Drug Administration (FDA) has ...

Serial Cell-Free DNA Sequencing in ROS1 Fusion–Positive Lung Cancers During Treatment With Entrectinib Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib ...

In the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) has accepted ...

A new immunotherapy has been recommended for approval in Europe for use for some women with recurrent or advanced endometrial cancer, specifically, for women with tumors. The product is dostarlimab ...

Dostarlimab is an immunotherapy drug typically used to treat endometrial cancer. This study was the first time it was used to battle rectal cancer tumors. Usually, patients with rectal cancer must ...

Every patient in a small clinical trial at Memorial Sloan Kettering Cancer Center saw their rectal cancer vanish after ...

Dostarlimab, for patients with recurrent or advanced deficient mismatch repair endometrial cancer, and a companion diagnostic, were recently approved by the FDA. This month, the FDA granted ...

Many drugmakers last year fell victim to COVID-19 related FDA inspection delays that stalled drug approvals, and GlaxoSmithKline's oncology hopeful dostarlimab was not immune, the British Big Pharma ...